Jason L Gaglia MD
Diabetes, Lipid Metabolism, Parathyroid, Thyroid
Assistant Professor, Joslin Diabetes Center
Join to View Full Profile
1 Joslin PlRoom 470Boston, MA 02215
Phone+1 617-732-2675
Fax+1 617-732-2452
Dr. Gaglia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2003 - 2006- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2001 - 2003
Harvard Medical SchoolClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
MA State Medical License 2006 - 2027
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2011-2012
- Diabetes Recognition Program National Committee for Quality Assurance, 2010-2013
Clinical Trials
- Imaging of Type 1 Diabetes Progression Start of enrollment: 2012 Jan 01
- Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus Start of enrollment: 2014 Jan 01
- Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- An Atypical Presentation of Cytokine Release Syndrome With Signs of Arthritis During Treatment With Teplizumab in a Pediatric Patient.Courtney J Duckworth, Raymond J Kreienkamp, Evan C Rieger, Thinh H Nguyen, Jason L Gaglia
Diabetes Care. 2025-04-01 - Limitations in Achieving Glycemic Targets From CGM Data and Persistence of Severe Hypoglycemia in Adults With Type 1 Diabetes Regardless of Insulin Delivery Method.Lori M Laffel, Jennifer L Sherr, Jingwen Liu, Wendy A Wolf, Jeoffrey Bispham
Diabetes Care. 2025-02-01 - 1 citationsNovel Autologous Dendritic Cell Therapy AVT001 for Type 1 Diabetes.Jason L Gaglia, Heather L Daley, Nora K Bryant, Jerome Ritz, Tuochuan Dong
NEJM Evidence. 2024-07-01
Press Mentions
Novo Nordisk Aims to Break Mould with New Pill for DiabetesFebruary 21st, 2018
Eli Lilly's Diabetes Pill Takes Market Share from J&J;, AstraJanuary 5th, 2016- Unease Grows Among U.S. Doctors over Indian Drug QualityMarch 18th, 2014
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
